Sumitomo Pharma (TSE:4506) has drawn fresh attention after reporting a 29% rise in TWYMEEG® net sales in Japan for the third quarter of 2026 compared with the same period in 2025.
The TWYMEEG® update comes at a time when Sumitomo Pharma’s share price has climbed 46.66% over the past 90 days and 17.18% over the last month. Despite this, the year-to-date share price return is still down 23.36%. However, the 3-year total shareholder return of 298.31% and 12% over 1 year indicate that momentum may be rebuilding after a tougher spell for the stock.
Compare Sumitomo Pharma’s rebound with other potential recovery stories by scanning our hand picked 73 high quality undiscovered gems that show strong fundamentals that have not yet been fully reflected in recent share prices.
Sumitomo Pharma’s share price has run hard, yet the latest ¥1,886 level still sits well below both analyst targets and some fair value estimates. Is the recent surge already generous, or is the discount still meaningful?
Most Popular Narrative: 15.4% Undervalued
On the most followed view, Sumitomo Pharma’s fair value of ¥2,228.57 sits comfortably above the latest ¥1,886 share price. This puts a spotlight on what is driving that gap and whether the underlying story justifies it.
Ambitious oncology and regenerative medicine programs such as enzomenib, nuvisertib and iPS cell therapies require accelerated clinical activity and shared development with partners. This may lift R&D outlays faster than product contributions, reducing near to medium term earnings leverage.
See why 1 investors see Sumitomo Pharma as 15% undervalued.
Result: Fair Value of ¥2,228.57 (UNDERVALUED)
Still, parts of the Sumitomo Pharma story cut the other way, with heavy reliance on ORGOVYX and GEMTESA and rising R&D needs potentially squeezing future earnings power.
Find out about the key risks to this Sumitomo Pharma narrative.
Next Steps
Conflicted about whether Sumitomo Pharma’s recent surge matches the underlying story, or still leaves room on the table? Move quickly and test the numbers yourself by weighing its 3 key rewards and 3 important warning signs
Looking for more Sumitomo Pharma investment ideas?
If Sumitomo Pharma has sharpened your focus, do not stop here. The next smart move could be sitting in plain sight on a different ticker.
- Target dependable cash generators by scanning a curated set of companies with strong cash flows and attractive valuations using our 13 high quality undervalued stocks.
- Prioritise resilience by reviewing a 21 resilient stocks with low risk scores that filters for businesses with steadier risk profiles and fewer financial red flags.
- Hunt for tomorrow’s potential standouts before the crowd notices by running through our 73 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com